Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

NCT00280631 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT00280631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00280631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
Lead sponsor
Telik
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2006
Completion date
June 30, 2008
Enrollment
49 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)